Celularity (CELU) FDA Approvals $0.81 +0.03 (+3.23%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Celularity's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Celularity (CELU). Over the past two years, Celularity has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PDA-002. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. PDA-002 FDA Regulatory Events PDA-002 is a drug developed by Celularity for the following indication: For treating Facioscapulohumeral Muscular Dystrophy (FSHD). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - October 14,2025Publication Phase 2Drug: PDA-002Announced Date: October 14, 2025Indication: For treating Facioscapulohumeral Muscular Dystrophy (FSHD).AnnouncementCelularity Inc. announced the publication of its Phase 2 study titled "Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial," in the International Wound Journal.AI SummaryCelularity Inc. announced the publication of its Phase 2 study of PDA-002 in diabetic foot ulcer patients with and without peripheral artery disease (PAD) in the International Wound Journal. This trial tested the safety and effectiveness of PDA-002, a placenta-derived cell therapy, in complex wounds among diabetic patients. The study enrolled 159 adults across 35 U.S. sites. Participants received two intramuscular doses of PDA-002 at three dose levels or placebo. The main goal was complete wound closure within three months with healing lasting at least four more weeks. In PAD patients, the lowest dose (3 × 10^6 cells) achieved a 38.5% closure rate versus 22.6% with placebo. Treated patients healed faster, had fewer cases of gangrene and infections, and had no serious side effects over two years. These findings support further trials to confirm PDA-002 as a novel regenerative therapy for hard-to-treat diabetic ulcers.Read Announcement Celularity FDA Events - Frequently Asked Questions Has Celularity received FDA approval? As of now, Celularity (CELU) has not received any FDA approvals for its therapy in the last two years. What drugs has Celularity submitted to the FDA? In the past two years, Celularity (CELU) has reported FDA regulatory activity for PDA-002. What is the most recent FDA event for Celularity? The most recent FDA-related event for Celularity occurred on October 14, 2025, involving PDA-002. The update was categorized as "Publication," with the company reporting: "Celularity Inc. announced the publication of its Phase 2 study titled "Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial," in the International Wound Journal." What conditions do Celularity's current drugs treat? Currently, Celularity has one therapy (PDA-002) targeting the following condition: For treating Facioscapulohumeral Muscular Dystrophy (FSHD).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsApyx Medical FDA EventsAtossa Genetics FDA EventsBiogen FDA EventsBioLineRx FDA EventsCAMP4 Therapeutics FDA EventsCelcuity FDA EventsClimb Bio FDA EventsCorvus Pharmaceuticals FDA EventsEditas Medicine FDA EventsEyepoint Pharmaceuticals FDA EventsGenprex FDA EventsGT Biopharma FDA EventsMiNK Therapeutics FDA EventsINmune Bio FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Cue Biopharma FDA Events Biomea Fusion FDA Events KALA BIO FDA Events Oncolytics Biotech FDA Events Aldeyra Therapeutics FDA Events NRx Pharmaceuticals FDA Events Anixa Biosciences FDA Events Cypherpunk Technologies FDA Events Athira Pharma FDA Events Spruce Biosciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:CELU last updated on 10/14/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe Rare Earth Shift Few Saw ComingRare earth elements are the hidden backbone of electric vehicles, modern defense technology, and advanced elec...i2i Marketing Group, LLC | SponsoredYou'll buy SpaceX at $1.75 trillion. Insiders bought at $20 billion.Insiders bought SpaceX at $20 billion. Banks got in at $100 billion. By the time it hits your brokerage accoun...Behind the Markets | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredThe system holding the dollar together is gone…Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - October 14,2025Publication Phase 2Drug: PDA-002Announced Date: October 14, 2025Indication: For treating Facioscapulohumeral Muscular Dystrophy (FSHD).AnnouncementCelularity Inc. announced the publication of its Phase 2 study titled "Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial," in the International Wound Journal.AI SummaryCelularity Inc. announced the publication of its Phase 2 study of PDA-002 in diabetic foot ulcer patients with and without peripheral artery disease (PAD) in the International Wound Journal. This trial tested the safety and effectiveness of PDA-002, a placenta-derived cell therapy, in complex wounds among diabetic patients. The study enrolled 159 adults across 35 U.S. sites. Participants received two intramuscular doses of PDA-002 at three dose levels or placebo. The main goal was complete wound closure within three months with healing lasting at least four more weeks. In PAD patients, the lowest dose (3 × 10^6 cells) achieved a 38.5% closure rate versus 22.6% with placebo. Treated patients healed faster, had fewer cases of gangrene and infections, and had no serious side effects over two years. These findings support further trials to confirm PDA-002 as a novel regenerative therapy for hard-to-treat diabetic ulcers.Read Announcement
Free CELU Stock Alerts